Figure 4

Summary of the gene regulatory effects of IFN-beta therapy and the differences in expression between the two patient cohorts. Before the start of therapy, 11 genes were expressed at significantly higher levels in the group of patients with elevated IFN-like activity (MX1_high, n = 7). The pathway expression profile of those patients was not significantly influenced by subcutaneous IFN-beta therapy. In comparison, 25 genes were up- or downregulated in response to therapy in the MX1_low group (n = 30), including all 11 genes that were elevated in the MX1_high group at baseline. After 1 month of therapy, no significant differences in gene expression could be observed between the cohorts.